Lixte Biotechnology (LIXT)
(Delayed Data from NSDQ)
$2.32 USD
-0.08 (-3.33%)
Updated Jul 26, 2024 03:17 PM ET
After-Market: $2.49 +0.17 (7.33%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Lixte Biotechnology Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 5 | 6 | 7 | 3 | 2 |
Income After Depreciation & Amortization | -5 | -6 | -7 | -3 | -2 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -5 | -6 | -7 | -3 | -2 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -5 | -6 | -7 | -3 | -2 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -5 | -6 | -7 | -3 | -2 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -5 | -6 | -7 | -3 | -2 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -5 | -6 | -7 | -3 | -2 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1.92 | 1.58 | 1.35 | 1.13 | NA |
Diluted EPS Before Non-Recurring Items | -2.66 | -4.00 | -5.00 | -2.90 | NA |
Diluted Net EPS (GAAP) | -2.66 | -4.00 | -5.00 | -2.90 | NA |
Fiscal Year end for Lixte Biotechnology Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.97 | 1.03 | 1.02 | 1.67 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -0.97 | -1.03 | -1.02 | -1.67 |
Non-Operating Income | NA | 0.00 | 0.00 | 0.01 | 0.00 |
Interest Expense | NA | 0.01 | 0.01 | 0.00 | 0.00 |
Pretax Income | NA | -0.97 | -1.03 | -1.02 | -1.67 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -0.97 | -1.03 | -1.02 | -1.67 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -0.97 | -1.03 | -1.02 | -1.67 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 2.25 | 2.52 | 2.08 | 1.67 |
Diluted EPS Before Non-Recurring Items | NA | -0.43 | -0.41 | -0.49 | -1.00 |
Diluted Net EPS (GAAP) | NA | -0.43 | -0.37 | -0.49 | -1.00 |